Latest Updates of Viva Biotech`s Portfolio Companies
08 Jan 2025 //
PR NEWSWIRE
VivaVision Announces Positive VVN461 Results for Post-Op Inflammation
04 Dec 2024 //
GLOBENEWSWIRE
VivaVision’s VVN461 Excels in Phase 2 Cataract Inflammation Trial
03 Dec 2024 //
PR NEWSWIRE
Vivavision’s Phase IIa study of ophthalmic solution meets primary endpoints
05 Jun 2023 //
CLINICAL TRIALS ARENA